Vyome net loss widens to $719,683 in Q2 FY26; revenue falls to $26,955
Reuters2026/08/12 20:33- Vyome Holdings posted a net loss of $719,683 for the three months ended June 30, 2026, widening from $308,760 a year earlier.
- Revenue fell 46.03% to $26,955, driven by lower product sales and royalty income from Sun Pharma.
- Research and development expense surged more than doubled to $506,723 due to scaling regulatory consulting and CMC preparation for VT-1953.
- General and administrative costs rose 37.49% to $364,891 on higher public-company professional fees, staffing, and stock-based compensation.
- VT-1953 received FDA written feedback on its pre-IND package; plans include a Type C meeting before advancing a pivotal program.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Stellar network stablecoin transfer volume increases by 50%, supply decreases by 11.7%
The U.S. Treasury market remains overheated! Besent expands repo program, emphasizing "this is not quantitative easing"
U.S. Treasury Secretary Janet Yellen stated on Tuesday that the Treasury's decision last month to expand the buyback program for older-dated U.S. Treasury bonds was mainly aimed at "cooling down" the bond market, which has been heating up recently, and helping the market return to a more balanced state.
Lupatech ratifies Mipel’s BRL 1.59 million private commercial note issuance
Crypto prices
More
